Zura Bio Limited (NASDAQ:ZURA) Receives Average Recommendation of “Buy” from Brokerages

Shares of Zura Bio Limited (NASDAQ:ZURA) have been assigned a consensus recommendation of “Buy” from the seven ratings firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $15.80.

ZURA has been the subject of several research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zura Bio in a research note on Wednesday, December 11th. HC Wainwright restated a “neutral” rating and set a $5.00 price objective on shares of Zura Bio in a research note on Tuesday, December 24th.

Zura Bio Trading Up 18.5 %

Shares of Zura Bio stock opened at $1.28 on Monday. The company has a 50-day moving average of $1.60 and a 200 day moving average of $2.89. Zura Bio has a 1 year low of $1.07 and a 1 year high of $6.35.

Institutional Trading of Zura Bio

A number of institutional investors have recently made changes to their positions in ZURA. JPMorgan Chase & Co. boosted its holdings in shares of Zura Bio by 12,060.8% during the 4th quarter. JPMorgan Chase & Co. now owns 2,633,185 shares of the company’s stock valued at $6,583,000 after acquiring an additional 2,611,532 shares during the last quarter. Braidwell LP purchased a new stake in shares of Zura Bio during the 3rd quarter valued at about $10,040,000. Sphera Funds Management LTD. purchased a new stake in shares of Zura Bio during the 3rd quarter valued at about $2,999,000. Millennium Management LLC boosted its holdings in shares of Zura Bio by 1,499.0% during the 4th quarter. Millennium Management LLC now owns 701,278 shares of the company’s stock valued at $1,753,000 after acquiring an additional 657,420 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Zura Bio by 70.6% during the 3rd quarter. Geode Capital Management LLC now owns 912,625 shares of the company’s stock valued at $3,706,000 after acquiring an additional 377,545 shares during the last quarter. Hedge funds and other institutional investors own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.